Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
| Autor: | Sun Young Kim, Pil Soon Jang, Hyun Mo Kang, Jeong Eun Lee, Sun Jung Kwon, Sung Soo Jung, Yun Sun Lee, Jin Young An, Ju Ock Kim |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Neutropenia medicine.disease Infectious Diseases Docetaxel Internal medicine Toxicity medicine Every Three Weeks Adenocarcinoma Premedication Lung cancer business medicine.drug |
| Zdroj: | Tuberculosis and Respiratory Diseases. 58:465 |
| ISSN: | 2005-6184 1738-3536 |
| DOI: | 10.4046/trd.2005.58.5.465 |
| Popis: | Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second-line chemotherapy, for which Docetaxel () has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum-based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first-line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either or , with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression-free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (: 6.6 months, p = 0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment-related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small-cell lung cancer who failed first-line platinum-based chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|